Personalized mRNA Vaccine Shows Significant Reduction in Melanoma Recurrence or Death

New clinical trial results indicate that the personalized mRNA-based melanoma vaccine, intismeran, substantially reduces the risk of cancer recurrence or death within two years. The Australian-led trial involved 1,137 patients who had undergone melanoma removal but remained at high risk of recurrence.